Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS). The ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

Despite transformative advances in materials discovery, real-world performance still hinges on an often-overlooked variable: processing. To bridge the gap between discovery and deployment, processing ...

American business services giant Conduent has confirmed that a 2024 data breach has impacted over 10.5 million people, according to notifications filed with the US Attorney General's offices. Japanese ...

The latest price target for Morgan Stanley (NYSE:MS) was reported by JP Morgan on October 21, 2025. The analyst firm set a price target for $157.00 expecting MS to fall to within 12 months (a possible ...

This data feed is not available at this time. Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.

Sanofi's oral BTK inhibitor tolebrutinib is heading towards an FDA decision in September as a potential treatment for multiple sclerosis (MS) after a priority review by the US regulator. Tolebrutinib ...